This report ( Aug 2006) has target 3.2 and takeover target $25.( page 5)
http://files.shareholder.com/downloads/X...
Now XOMA is traded at 3.2 and with higher rev. and more partners ( i.e Japen biggest phar company Takeda) and potential home-run drug Xoma052
It won\'t shot to the sky in one like DNDN, but will move up steady. imo
http://biz.yahoo.com/pz/070412/117221.ht...
``Having participated in the development of other biological drugs such as rituximab, etanercept and anakinra, I can say that I am excited about the potential of XOMA 052,\'\' said Alan Solinger, M.D. Vice President of Clinical Immunology at XOMA. ``We will be working with key opinion leaders in Type 2 diabetes as our first indication but I also look forward to developing XOMA 052 for its many other potential applications in IL-1 mediated diseases.
